CSL Seqirus expands U.S. influenza vaccine availability after 2026/27 campaign completion
Reuters reports CSL Seqirus expanded U.S. availability of its influenza vaccine following successful completion of the 2026/27 manufacturing campaign.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
CSL Seqirus Expands U.S. Influenza Vaccine Availability Ahead Of Flu Season
CANBERA (dpa-AFX) - Tuesday, CSL Seqirus, a business of CSL (CSL.AX), said it has expanded the availability of influenza vaccines in the U.S. following the successful completion of its 2026/27 manufacturing campaign.The company said most customer orders have already been shipped, with remaining del…
CSL Seqirus Expands U.S. Availability of Influenza Vaccine following Successful Completion of the 2026/27 Manufacturing Campaign
HOLLY SPRINGS, N.C., Sept. 29, 2026 // -- CSL Seqirus, a business of CSL (ASX:CSL), today announced expanded availability of influenza vaccine in the United States following the successful completion of its 2026/27 manufacturing campaign.With the majority of customer orders already shippe…